Obeidat Fatima Nouri, Ahram Mamoun, Al-Khader Ali, Mbaideen Suzan Al, Hassan Huda, Altarawneh Bushra, Battah Khairat
Dr. Fatima Nouri Obeidat, Department of Pathology and Microbiology and Forensic Medicine,, School of Medicine,, University of Jordan,, Amman 11942, Jordan, T: +962-797737300,
Ann Saudi Med. 2018 Sep-Oct;38(5):326-335. doi: 10.5144/0256-4947.2018.326.
The clinical relevance of androgen receptors (ARs) expressed in breast cancer cells and the suggested prognostic impact has been an area of active research. The prevalence rate of AR expression in breast cancer has never been reported among Jordanian patients.
Determine the expression rate of ARs among invasive ductal breast cancer cases of different stages and molecular subtypes. Also, analyze the relationship between AR expression and clinicopathologic and immunohistochemical criteria, and assess the impact of AR expression on survival.
Retrospective medical record review.
Tertiary care hospital in Amman, Jordan.
Our study comprised only of cases of invasive ductal breast carcinoma of no special type among females from records during a 10-year period between 2006 and 2015. Immunohistochemical staining was considered positive if more than 10% of tumor nuclei showed positive staining.
The expression rate of ARs and the association of the expression rate with the clinicopathologic features of invasive breast cancer.
Immunohistochemical staining for AR revealed positive stain.ing in 180 (61.4%) cases, including approximately 50% of triple-negative breast cancer cases. AR positivity correlated with estrogen receptor (ER) status (P=.007) and smaller T size (P=.014). However, no significant association was found with any of the other variables. AR expression was positively associated with overall survival (P=.022) in general and in ER-positive cases (P=.012). However, in the multivariate Cox regression model, AR was not independently associated with survival.
These results were consistent with international reports showing a significant relationship of AR expression with ER status. In addition, AR expression was significantly associated with smaller tumor size. Although AR status was not independently associated with survival, our data suggest AR is a good prognostic factor.
Some clinical data were missing.
None.
乳腺癌细胞中雄激素受体（ARs）表达的临床相关性以及所提示的预后影响一直是积极研究的领域。约旦患者中乳腺癌AR表达的患病率从未有过报道。
确定不同分期和分子亚型的浸润性导管癌病例中ARs的表达率。此外，分析AR表达与临床病理及免疫组化标准之间的关系，并评估AR表达对生存的影响。
回顾性病历审查。
约旦安曼的三级护理医院。
我们的研究仅包括2006年至2015年10年间记录中的女性非特殊类型浸润性导管癌病例。如果超过10%的肿瘤细胞核显示阳性染色，则免疫组化染色被认为是阳性。
ARs的表达率以及该表达率与浸润性乳腺癌临床病理特征的关联。
293例。
AR的免疫组化染色显示180例（61.4%）呈阳性染色，包括约50%的三阴性乳腺癌病例。AR阳性与雌激素受体（ER）状态相关（P = 0.007）且T分期较小（P = 0.014）。然而，未发现与任何其他变量有显著关联。总体而言，AR表达与总生存期呈正相关（P = 0.022），在ER阳性病例中也是如此（P = 0.012）。然而，在多变量Cox回归模型中，AR与生存无独立相关性。
这些结果与国际报告一致，表明AR表达与ER状态存在显著关系。此外，AR表达与较小的肿瘤大小显著相关。虽然AR状态与生存无独立相关性，但我们的数据表明AR是一个良好的预后因素。
一些临床数据缺失。
无。
Zotero 插件
